Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy

WARREN, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced it has received the previously reported $1 million in funding to advance Tevogen.AI, its artificial intelligence–powered drug discovery and development program.

Read more at globenewswire.com